• If you are wondering whether BioCryst Pharmaceuticals is offering good value at its recent price, this breakdown will help you weigh what that current tag might really mean.
• The stock recently closed at US$9.21, with returns of 5.3% over 7 days, 36.2% over 30 days, 22.8% year to date, 20.5% over 1 year, 12.7% over 3 years and a 15.2% decline over 5 years. This gives you a wide range of outcomes to think about.
• Recent attention on BioCryst has been shaped by ongoing interest in its pipeline and funding position. These often influence how investors weigh risk and potential reward in smaller biotech names. These themes help frame how the market might be reacting to new updates and shifting expectations around the business.
• BioCryst currently scores 5 out of 6 on a valuation checklist of discounted cash flow, earnings, revenue and asset based measures. The sections ahead will compare these methods while also pointing to an even more complete way to think about valuation at the end of the article.

Approach 1: BioCryst Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model takes projected future cash flows, then discounts them back to today to estimate what the entire business might be worth per share.

For BioCryst Pharmaceuticals, the model used is a 2 Stage Free Cash Flow to Equity approach, based on cash flows reported and estimated in US$. The latest trailing twelve month free cash flow is about $344.3 million. Analysts have provided detailed estimates through 2030, with Simply Wall St extrapolating further years. Within those projections, free cash flow for 2030 is set at $586.1 million, with a range of annual figures between 2026 and 2035 informing the calculation.

When all of those forecast cash flows are discounted back to today, the model arrives at an estimated intrinsic value of about US$76.91 per share. Compared to the recent share price of US$9.21, this output suggests the stock screens as around 88.0% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests BioCryst Pharmaceuticals is undervalued by 88.0%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: BioCryst Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to see how much investors are paying for each dollar of earnings. It gives you a quick sense of how the market is weighing the trade off between what the business earns today and what it might earn in the future.

Higher growth expectations or lower perceived risk often go together with a higher P/E, while slower growth or higher risk typically line up with a lower multiple. BioCryst Pharmaceuticals currently trades on a P/E of 8.75x. That sits well below the Biotechs industry average P/E of about 20.05x and also below the peer group average of 30.27x, so the stock is pricing in lower expectations than many sector names.

Simply Wall St’s Fair Ratio is a proprietary estimate of what a more suitable P/E might be once factors like earnings growth, industry, profit margin, market cap and company specific risks are taken into account. Because it blends these elements, it can offer a more tailored anchor point than a simple comparison with industry or peer averages. For BioCryst, the Fair Ratio is 19.53x, which is materially above the current 8.75x P/E. This indicates that the shares screen as undervalued on this basis.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your BioCryst Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives bring that to life by letting you set a story for BioCryst Pharmaceuticals that links your view on its products, pipeline and risks to explicit forecasts for revenue, earnings, margins and a Fair Value. You can then compare this with the current price to decide whether the stock looks expensive or cheap. Because these Narratives on Simply Wall St’s Community page refresh when news or earnings arrive, you can see in real time how a more optimistic view that points to a Fair Value of about US$32.00 or a more cautious stance nearer US$11.00 would each translate into different decisions based on the same share price.

Do you think there's more to the story for BioCryst Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.